Related Experiment Videos
Irinotecan and radiation in combined-modality therapy for solid tumors
1Center for Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-5671, USA. Hak.Choy@mcmail.Vanderbilt.edu
Oncology (Williston Park, N.Y.)
|August 11, 2001
Summary
Irinotecan, a topoisomerase I inhibitor, shows potential as a radiosensitizer. Clinical trials are exploring its use with radiotherapy to improve outcomes for solid tumors.
Area of Science:
- Oncology
- Pharmacology
- Radiation Oncology
Background:
- Irinotecan (CPT-11) is a camptothecin derivative targeting topoisomerase I.
- It stabilizes DNA-topoisomerase I complexes, potentially leading to cell death.
- In vitro and in vivo studies suggest irinotecan acts as a radiosensitizer.
Purpose of the Study:
- To review the current status of irinotecan used concurrently with radiotherapy.
- To explore its potential in improving local control for solid tumors.
Main Methods:
- Review of in vitro and in vivo data.
- Overview of early clinical trials in combined-modality settings.
Main Results:
- Evidence supports irinotecan's role as a radiosensitizer.
- Concurrent chemoradiation with irinotecan is under investigation for various solid tumors.
Conclusions:
- Irinotecan shows promise as a radiosensitizer in solid tumor treatment.
- Further clinical trials are warranted to establish its efficacy in combined-modality therapy.